Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2013; 19(8): 1318-1321
Published online Feb 28, 2013. doi: 10.3748/wjg.v19.i8.1318
Published online Feb 28, 2013. doi: 10.3748/wjg.v19.i8.1318
Figure 1 Clinical course of cases.
A: Case 1, showing alanine transaminase (ALT) and Bcr-Abl/AblIS ratio over time; B: Case 2, showing ALT and Bcr-Abl/AblIS ratio over time; C: Case 3, showing ALT and Bcr-Abl/AblIS ratio over time. IM: Imatinib mesylate; IS: International scale.
- Citation: Lai GM, Yan SL, Chang CS, Tsai CY. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol 2013; 19(8): 1318-1321
- URL: https://www.wjgnet.com/1007-9327/full/v19/i8/1318.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i8.1318